Phase 1/2 biotech developing allogeneic therapies for hemophilia A and diabetes.
Industry: Health Care
First Day Return: +93.2%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 11/13/2020 |
Offer Price | $18.00 |
Price Range $17.00 - $19.00 | |
Offer Shares (mm) | 7.0 |
Deal Size ($mm) | $126 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 12/03/2020 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $126 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | Cambridge, MA, United States |
Founded | 2015 |
Employees at IPO | 96 |
Website www.sigilon.com |